Biolinq’s needle-free Shine wearable has received FDA approval for over-the-counter use, marking a significant step in consumer glucose monitoring and challenging traditional medical device regulations.
Biolinq Incorporated said on Thursday that the US Food and Drug Administration has cleared its Shine wearable for over-the-counter use, a move that allows the glucose sensor to be sold without a prescription. The company said the decision follows an earlier FDA De Novo classification in 2025 and marks another regulatory step for the San Diego-based health technology firm.
The device is a needle-free patch worn on the forearm that uses a colour-coded light display to show whether glucose is within, above or below target range. Biolinq says the product is designed to work both with and without a phone, and also combines information on activity and sleep in one wearable system.
According to the company, Shine is intended for adults aged 22 and older who do not use insulin. It is designed to provide general information about glucose patterns and trends rather than exact glucose readings for urgent medical decisions, including insulin dosing or medication changes.
The clearance comes against a broader backdrop of rising interest in consumer glucose monitoring. The FDA’s own clearance process for medical devices is designed to determine whether a product is substantially equivalent to one already on the market, while the agency has also recently expanded over-the-counter access to continuous glucose monitors in the United States. Biolinq says its product differs from conventional monitors because it uses semiconductor-based microsensors placed just below the skin’s surface and offers glucose, activity and sleep feedback in a single device.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
